Extension Protocol for Patients With Chronic Myelogenous Leukemia, Malignant Melanoma or Renal Cell Carcinoma That Have Responded to Treatment With Pegylated-Interferon α-2a or Roferon-A® in Prior Clinical Studies

Trial Profile

Extension Protocol for Patients With Chronic Myelogenous Leukemia, Malignant Melanoma or Renal Cell Carcinoma That Have Responded to Treatment With Pegylated-Interferon α-2a or Roferon-A® in Prior Clinical Studies

Completed
Phase of Trial: Phase II/III

Latest Information Update: 11 Jan 2017

At a glance

  • Drugs Interferon alpha-2a (Primary) ; Peginterferon alfa-2a (Primary)
  • Indications Chronic myeloid leukaemia; Malignant melanoma; Renal cancer
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 07 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 08 Jun 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top